Amicus Therapeutics (NASDAQ:FOLD) was raised by equity researchers SVB Leerink from a “market performance” rating to an “outperform” rating in a report on Thursday, reports The Fly.

A number of other research analysts have also recently published reports on the company. Stifel Nicolaus downgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and raised its target price for the company from $12.00 to $16.00 in a Monday, November 15 research note. JPMorgan Chase & Co. upgraded Amicus Therapeutics from a “neutral” rating to an “overweight” rating and lowered its target price for the company from $17.11 to $16.00 in a Thursday, September 30 research note . Finally, Cantor Fitzgerald cut his price target on Amicus Therapeutics from $16.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday. Three investment analysts gave the stock a hold rating and seven gave the company a buy rating. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $15.00.

Shares of Amicus Therapeutics traded down $0.21 during Thursday’s trading, hitting $9.92. 191,003 shares of the company have been traded, against an average volume of 2,958,633. The company has a quick ratio of 5.19, a current ratio of 5.37 and a leverage ratio of 1.03. Amicus Therapeutics has a 12-month low of $8.40 and a 12-month high of $23.72. The company has a 50-day moving average price of $11.27 and a 200-day moving average price of $10.71. The company has a market capitalization of $2.76 billion, a price-earnings ratio of -11.02 and a beta of 1.21.

Amicus Therapeutics (NASDAQ:FOLD) last reported results on Monday, November 8. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.18) by ($0.01). Amicus Therapeutics had a negative net margin of 81.17% and a negative return on equity of 84.62%. The company posted revenue of $79.55 million in the quarter, against analyst estimates of $81.42 million. In the same period a year earlier, the company posted ($0.22) earnings per share. On average, equity research analysts expect Amicus Therapeutics to post -0.77 EPS for the current fiscal year.

Separately, COO Bradley L. Campbell sold 3,000 shares of the company in a trade dated Wednesday, Dec. 22. The stock was sold at an average price of $11.70, for a total transaction of $35,100.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Additionally, COO Bradley L. Campbell sold 10,515 shares of the company in a trade dated Monday, Nov. 1. The stock was sold at an average price of $11.32, for a total value of $119,029.80. The disclosure of this sale can be found here. Insiders sold 175,536 shares of the company valued at $2,065,762 in the past ninety days. 2.10% of the shares are held by insiders.

A number of large investors have recently increased or reduced their holdings in FOLD. The Canada Pension Plan Investment Board increased its position in Amicus Therapeutics shares by 27,670.0% in the second quarter. The Canada Pension Plan Investment Board now owns 2,777 shares of the biopharmaceutical company valued at $27,000 after buying 2,767 more shares in the last quarter. Dark Forest Capital Management LP increased its position in Amicus Therapeutics shares by 1,967.5% in the third quarter. Dark Forest Capital Management LP now owns 4,838 shares of the biopharmaceutical company valued at $46,000 after buying an additional 4,604 shares in the last quarter. Copernicus Capital Management LLC acquired a new position in shares of Amicus Therapeutics in the third quarter valued at approximately $96,000. Paloma Partners Management Co acquired a new position in shares of Amicus Therapeutics in the second quarter worth approximately $98,000. Finally, CIBC Asset Management Inc. acquired a new position in shares of Amicus Therapeutics in the third quarter valued at approximately $101,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc operates as a biotechnology company. The company is focused on the discovery, development and delivery of medicines for people with metabolic diseases. Its product portfolio includes the first and only precision oral medicine approved for people with Fabry disease who have favorable genetic variants, a new clinical-stage treatment paradigm for Pompe disease and a gene therapy portfolio for rare diseases.

Feature article: Return on equity (ROE)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Amicus Therapeutics right now?

Before you consider Amicus Therapeutics, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Amicus Therapeutics wasn’t on the list.

Although Amicus Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here